CN112826926A - 一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 - Google Patents
一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 Download PDFInfo
- Publication number
- CN112826926A CN112826926A CN202110269038.9A CN202110269038A CN112826926A CN 112826926 A CN112826926 A CN 112826926A CN 202110269038 A CN202110269038 A CN 202110269038A CN 112826926 A CN112826926 A CN 112826926A
- Authority
- CN
- China
- Prior art keywords
- powder
- antioxidant enzyme
- diabetes
- preparation
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 17
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 13
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229910052748 manganese Inorganic materials 0.000 title claims abstract description 12
- 239000011572 manganese Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 7
- 229920001353 Dextrin Polymers 0.000 claims abstract description 7
- 239000004375 Dextrin Substances 0.000 claims abstract description 7
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 7
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 7
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 claims abstract description 7
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 claims abstract description 7
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims abstract description 7
- 235000019425 dextrin Nutrition 0.000 claims abstract description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 7
- 239000000600 sorbitol Substances 0.000 claims abstract description 7
- 229940013618 stevioside Drugs 0.000 claims abstract description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019202 steviosides Nutrition 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000000265 homogenisation Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000009811 Momordica charantia Nutrition 0.000 claims description 3
- 240000000249 Morus alba Species 0.000 claims description 3
- 235000008708 Morus alba Nutrition 0.000 claims description 3
- 240000001949 Taraxacum officinale Species 0.000 claims description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 3
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 3
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 206010054044 Diabetic microangiopathy Diseases 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 201000009101 diabetic angiopathy Diseases 0.000 abstract description 3
- 210000003038 endothelium Anatomy 0.000 abstract description 3
- 230000024883 vasodilation Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000011506 response to oxidative stress Effects 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开的属于糖尿病治疗技术领域，具体为一种基于锰型抗氧化酶的糖尿病改善药物的制备方法，该基于锰型抗氧化酶的糖尿病改善药物的制备步骤如下：步骤一：将燕麦‑β葡聚糖、山梨糖醇放入均质机中均质；步骤二：将均质完成的材料加入苦瓜粉、玉米须、葛根粉、桑叶粉、蒲公英粉、黄精粉和超氧化物歧化酶MnSOD搅拌混合；步骤三：将混合后的材料过滤；步骤四：将过滤完后的物料加入脱脂奶粉、抗性糊精、甜菊糖苷、硬脂酸镁和1％‑4％的水搅拌混合；步骤五：压片成型，本申请文件中，能够有效的补充抗氧化酶，清除过量的自由基，有效的保护胰岛细胞，避免自由基侵害，进而保证胰岛细胞的正常功能，同时改善内皮依赖性血管舒张和糖尿病微血管病变。
Description
技术领域
本发明涉及糖尿病治疗技术领域，具体为一种基于锰型抗氧化酶的糖尿病改善药物的制备方法。
背景技术
高血糖和高游离脂肪酸刺激的后果是高活性反应分子氧自由基增多，从而启动了氧化应激机制(高活性反应分子产生和抗氧化作用之间长期失衡而引起组织损伤)。这些活性分子可直接氧化和损伤DNA、蛋白质、脂类，还可作为功能性分子信号，激活细胞内多种应激敏感信号通路，这些信号通路与胰岛素抵抗和β细胞功能受损密切相关。
胰岛-β细胞也是氧化应激的重要靶点，胰岛β-细胞内抗氧化酶水平较低，故对氧自由基较为敏感。氧自由基可直接损伤胰岛β细胞，促进胰岛β-细胞凋亡，还可通过影响胰岛素信号传导通路间接抑制β细胞功能。胰岛Β-细胞受损，胰岛素分泌水平降低、分泌高峰延迟，血糖波动加剧，因而难以控制餐后血糖的迅速上升，对细胞造成更为显著的损害。
现有的药物中，不能够针对氧化应激和炎症反应去进行药物制备，不能够从胰岛-β细胞的氧化受损这一类根源问题上着手进行抗氧化治疗，导致不能很好的阻止或者干预调控糖尿病及其并发症的发生、发展，在人体胰岛-B细胞中，抗氧化酶--SOD、过氧化氢酶和谷胱甘肽过氧化物酶活性相对较低，因而对氧自由基介导的损害非常敏感，不能够有效的清除过量的自由基，以减少氧化应激和炎症反应，不利于促进胰岛细胞的修复。
发明内容
本部分的目的在于概述本发明的实施方式的一些方面以及简要介绍一些较佳实施方式。在本部分以及本申请的说明书摘要和发明名称中可能会做些简化或省略以避免使本部分、说明书摘要和发明名称的目的模糊，而这种简化或省略不能用于限制本发明的范围。
鉴于上述和/或现有糖尿病改善药物中存在的问题，提出了本发明。
因此，本发明的目的是提供一种基于锰型抗氧化酶的糖尿病改善药物的制备方法，能够有效的补充抗氧化酶，清除过量的自由基，有效的减少氧化应激和炎症反应，有效的保护胰岛细胞，避免自由基侵害，进而保证胰岛细胞的正常功能，同时改善内皮依赖性血管舒张和糖尿病微血管病变。
为解决上述技术问题，根据本发明的一个方面，本发明提供了如下技术方案：
一种基于锰型抗氧化酶的糖尿病改善药物的制备方法，该基于锰型抗氧化酶的糖尿病改善药物的制备步骤如下：
步骤一：将燕麦-β葡聚糖、山梨糖醇放入均质机中均质；
步骤二：将均质完成的材料加入苦瓜粉、玉米须、葛根粉、桑叶粉、蒲公英粉、黄精粉和超氧化物歧化酶MnSOD搅拌混合；
步骤三：将混合后的材料过60目筛过滤；
步骤四：将过滤完后的物料加入脱脂奶粉、抗性糊精、甜菊糖苷、硬脂酸镁和1％-4％的水搅拌混合；
步骤五：在温度为10-30℃、湿度在40％RH-55％RH的环境中压片成型。
作为本发明所述的一种基于锰型抗氧化酶的糖尿病改善药物的制备方法的一种优选方案，其中：按比例计，该药物由以下材料制备产生：
38％燕麦-β葡聚糖、9％山梨糖醇、7％苦瓜粉、8％玉米须、6.7％葛根粉、5％桑叶粉、4％蒲公英粉、4％黄精粉、10％超氧化物歧化酶MnSOD、5％脱脂奶粉、5％抗性糊精、0.3％甜菊糖苷、1％硬脂酸镁。
与现有技术相比：现有的药物中，不能够针对氧化应激和炎症反应去进行药物制备，不能够从胰岛-β细胞的氧化受损这一类根源问题上着手进行抗氧化治疗，导致不能很好的阻止或者干预调控糖尿病及其并发症的发生、发展，在人体胰岛-B细胞中，抗氧化酶--SOD、过氧化氢酶和谷胱甘肽过氧化物酶活性相对较低，因而对氧自由基介导的损害非常敏感，不能够有效的清除过量的自由基，以减少氧化应激和炎症反应，不利于促进胰岛细胞的修复，本申请文件中，能够有效的补充抗氧化酶，清除过量的自由基，有效的减少氧化应激和炎症反应，有效的保护胰岛细胞，避免自由基侵害，进而保证胰岛细胞的正常功能，同时改善内皮依赖性血管舒张和糖尿病微血管病变。
附图说明
为了更清楚地说明本发明实施方式的技术方案，下面将结合附图和详细实施方式对本发明进行详细说明，显而易见地，下面描述中的附图仅仅是本发明的一些实施方式，对于本领域普通技术人员来讲，在不付出创造性劳动性的前提下，还可以根据这些附图获得其它的附图。其中：
图1为本发明一种基于锰型抗氧化酶的糖尿病改善药物的制备方法的流程结构示意图。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂，下面结合附图对本发明的具体实施方式做详细的说明。
在下面的描述中阐述了很多具体细节以便于充分理解本发明，但是本发明还可以采用其他不同于在此描述的其它方式来实施，本领域技术人员可以在不违背本发明内涵的情况下做类似推广，因此本发明不受下面公开的具体实施方式的限制。
其次，本发明结合示意图进行详细描述，在详述本发明实施方式时，为便于说明，表示器件结构的剖面图会不依一般比例作局部放大，而且所述示意图只是示例，其在此不应限制本发明保护的范围。此外，在实际制作中应包含长度、宽度及深度的三维空间尺寸。
为使本发明的目的、技术方案和优点更加清楚，下面将结合附图对本发明的实施方式作进一步地详细描述。
本发明提供一种基于锰型抗氧化酶的糖尿病改善药物的制备方法，该基于锰型抗氧化酶的糖尿病改善药物的制备步骤如下：
步骤一：将燕麦-β葡聚糖、山梨糖醇放入均质机中均质；
步骤二：将均质完成的材料加入苦瓜粉、玉米须、葛根粉、桑叶粉、蒲公英粉、黄精粉和超氧化物歧化酶MnSOD搅拌混合；
步骤三：将混合后的材料过60目筛过滤；
步骤四：将过滤完后的物料加入脱脂奶粉、抗性糊精、甜菊糖苷、硬脂酸镁和1％-4％的水搅拌混合；
步骤五：在温度为10-30℃、湿度在40％RH-55％RH的环境中压片成型。
请再次参阅图1，按比例计，该药物由以下材料制备产生：
38％燕麦-β葡聚糖、9％山梨糖醇、7％苦瓜粉、8％玉米须、6.7％葛根粉、5％桑叶粉、4％蒲公英粉、4％黄精粉、10％超氧化物歧化酶MnSOD、5％脱脂奶粉、5％抗性糊精、0.3％甜菊糖苷、1％硬脂酸镁。
虽然在上文中已经参考实施方式对本发明进行了描述，然而在不脱离本发明的范围的情况下，可以对其进行各种改进并且可以用等效物替换其中的部件。尤其是，只要不存在结构冲突，本发明所披露的实施方式中的各项特征均可通过任意方式相互结合起来使用，在本说明书中未对这些组合的情况进行穷举性的描述仅仅是出于省略篇幅和节约资源的考虑。因此，本发明并不局限于文中公开的特定实施方式，而是包括落入权利要求的范围内的所有技术方案。
Claims (2)
1.一种基于锰型抗氧化酶的糖尿病改善药物的制备方法，其特征在于：该基于锰型抗氧化酶的糖尿病改善药物的制备步骤如下：
步骤一：将燕麦-β葡聚糖、山梨糖醇放入均质机中均质；
步骤二：将均质完成的材料加入苦瓜粉、玉米须、葛根粉、桑叶粉、蒲公英粉、黄精粉和超氧化物歧化酶MnSOD搅拌混合；
步骤三：将混合后的材料过60目筛过滤；
步骤四：将过滤完后的物料加入脱脂奶粉、抗性糊精、甜菊糖苷、硬脂酸镁和1％-4％的水搅拌混合；
步骤五：在温度为10-30℃、湿度在40％RH-55％RH的环境中压片成型。
2.根据权利要求1所述的一种基于锰型抗氧化酶的糖尿病改善药物的制备方法，其特征在于：按比例计，该药物由以下材料制备产生：
38％燕麦-β葡聚糖、9％山梨糖醇、7％苦瓜粉、8％玉米须、6.7％葛根粉、5％桑叶粉、4％蒲公英粉、4％黄精粉、10％超氧化物歧化酶MnSOD、5％脱脂奶粉、5％抗性糊精、0.3％甜菊糖苷、1％硬脂酸镁。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269038.9A CN112826926A (zh) | 2021-03-12 | 2021-03-12 | 一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269038.9A CN112826926A (zh) | 2021-03-12 | 2021-03-12 | 一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112826926A true CN112826926A (zh) | 2021-05-25 |
Family
ID=75930130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110269038.9A Pending CN112826926A (zh) | 2021-03-12 | 2021-03-12 | 一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112826926A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583087A (zh) * | 2004-05-22 | 2005-02-23 | 刘贤英 | 一种降糖与防治糖尿病并发症的中药保健药物及制备工艺 |
| CN103202370A (zh) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | 一种降糖茶及其制备方法 |
| CN103285231A (zh) * | 2013-05-13 | 2013-09-11 | 刘扬 | 一种用于糖尿病辅助治疗的药物组合物及其制法 |
| CN107468898A (zh) * | 2017-09-11 | 2017-12-15 | 邹立影 | 一种糖尿病患者专用食品及其制作方法 |
| CN110251655A (zh) * | 2019-07-31 | 2019-09-20 | 张先奇 | 一种用于治疗糖尿病的药物组合物及其制备方法 |
| CN111714573A (zh) * | 2020-06-30 | 2020-09-29 | 广州贝塔健康生物科技有限公司 | 治疗糖尿病的燕麦葡聚糖颗粒及其制作工艺 |
-
2021
- 2021-03-12 CN CN202110269038.9A patent/CN112826926A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583087A (zh) * | 2004-05-22 | 2005-02-23 | 刘贤英 | 一种降糖与防治糖尿病并发症的中药保健药物及制备工艺 |
| CN103202370A (zh) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | 一种降糖茶及其制备方法 |
| CN103285231A (zh) * | 2013-05-13 | 2013-09-11 | 刘扬 | 一种用于糖尿病辅助治疗的药物组合物及其制法 |
| CN107468898A (zh) * | 2017-09-11 | 2017-12-15 | 邹立影 | 一种糖尿病患者专用食品及其制作方法 |
| CN110251655A (zh) * | 2019-07-31 | 2019-09-20 | 张先奇 | 一种用于治疗糖尿病的药物组合物及其制备方法 |
| CN111714573A (zh) * | 2020-06-30 | 2020-09-29 | 广州贝塔健康生物科技有限公司 | 治疗糖尿病的燕麦葡聚糖颗粒及其制作工艺 |
Non-Patent Citations (4)
| Title |
|---|
| 王文霞;贾伟平;: "锰超氧化物歧化酶与糖尿病慢性并发症", 上海医学, no. 04 * |
| 范强;杨丽霞;薛燕芳;白宇;姜良恩;刘铜华;: "2型糖尿病氧化应激与单味中药干预研究", 时珍国医国药, no. 07 * |
| 董吉林;陈明;申瑞玲;刘延奇;: "燕麦β-葡聚糖对STZ致Ⅱ型糖尿病小鼠胰岛素抵抗的影响", 郑州轻工业学院学报(自然科学版), no. 02 * |
| 金昕;陶枫;陆灏;沈远东;: "中药抗氧化在糖尿病中应用研究进展", 上海中医药大学学报, no. 04 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ayua et al. | Polyphenolic inhibition of enterocytic starch digestion enzymes and glucose transporters for managing type 2 diabetes may be reduced in food systems | |
| Ou et al. | In vitro study of possible role of dietary fiber in lowering postprandial serum glucose | |
| Tas et al. | In-vivo, hypoglycemic, hypolipidemic and oxidative stress inhibitory activities of Myrtus communis L. fruits hydroalcoholic extract in normoglycemic and streptozotocin-induced diabetic rats. | |
| CN107094843A (zh) | 一种控血糖保健饼干及其制造方法 | |
| CN106689959A (zh) | 一种辅助调节血糖的固体饮料 | |
| CN103610752A (zh) | 一种具有降血糖作用的功能性食品及其制备方法 | |
| CN114632101B (zh) | 一种广东虫草减肥降脂护肝复方及其制备方法和应用 | |
| Arya et al. | Diosgenin: An ingress towards solving puzzle for diabetes treatment | |
| CN112826926A (zh) | 一种基于锰型抗氧化酶的糖尿病改善药物的制备方法 | |
| Chen et al. | Effects of Rosa roxburghii Tratt fruit and its active ingredients on glucose and lipid metabolism in type 2 diabetic mice. | |
| CN107788451A (zh) | 一种供糖尿病患者食用的配方食品 | |
| Zhang et al. | Protective mechanism of Fagopyrum esculentum Moench. Bee pollen EtOH extract against type II diabetes in a high-fat diet/streptozocin-induced C57BL/6J mice | |
| CN114177247A (zh) | 一种抗癌控血糖桦褐孔菌纯粉片及其制备方法与应用 | |
| Gong et al. | Effects of crude flavonoids from tatary buckwheat on alloxan-induced oxidative stress in mice | |
| KP et al. | Okra Infusion Water Improving Stress Oxidative and Inflammatory Markers on Hyperglycemic Rats. | |
| KR101326002B1 (ko) | 당뇨병 개선을 위한 혈당 저하 및 조절용 조성물 | |
| CN111494440A (zh) | 一种蒺藜中降血糖成分皂苷的提取纯化及制备技术和蒺藜皂苷提取物与应用 | |
| CN111450136A (zh) | 一种牡蛎葛根复合颗粒及其制备方法 | |
| CN111165709A (zh) | 一种具有血糖控制功能的固体饮料及其制备方法 | |
| CN107088206B (zh) | 一种桑白皮提取物的制备方法及其应用 | |
| KR100697184B1 (ko) | 인삼과 상엽과 바나바엽을 주재로 한 혈당강하용 기능성 식품 및 그 제조방법 | |
| CN103549417B (zh) | 一种洋葱苦瓜分散片及其生产工艺 | |
| CN108578556A (zh) | 一种降血糖降血脂的保健品及其制备方法 | |
| CN114451560A (zh) | 一种糖尿病患者用膳食组合物及其应用 | |
| CN107582896A (zh) | 一种具有降低血糖血脂作用的制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210525 |
|
| WD01 | Invention patent application deemed withdrawn after publication |